# Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

> **NCT00052949** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 91 (estimated)

## Conditions studied

- Recurrent Small Cell Lung Cancer

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00052949
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2013-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052949, "Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00052949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*